Application Share:
The oncology and chemotherapy sector dominates the implantable pump market, accounting for nearly 29% of overall infusion system revenue.
With Dr. Kasi trialing 36 HAI patients & some pre-dose LL / liver washout, then looks like we can add competitive interest from the $9B HAI pump market, to the Leronlimab paradim potential(s)....
https://provider.healthybluemo.com/medpolicie...206.html...